Targeting cancer with small-molecule pan-KRAS degraders

被引：17

作者：

Popow, Johannes ^{[1
]}

Farnaby, William ^{[2
,3
]}

Gollner, Andreas ^{[1
]}

Kofink, Christiane ^{[1
]}

Fischer, Gerhard ^{[1
]}

Wurm, Melanie ^{[1
]}

Zollman, David ^{[2
,3
]}

Wijaya, Andre ^{[2
,3
]}

Mischerikow, Nikolai ^{[1
]}

Hasenoehrl, Carina ^{[1
]}

Prokofeva, Polina ^{[4
]}

Arnhof, Heribert ^{[1
]}

Arce-Solano, Silvia ^{[1
]}

Bell, Sammy ^{[5
]}

Boeck, Georg ^{[1
]}

Diers, Emelyne ^{[3
]}

Frost, Aileen B. ^{[2
,3
]}

Goodwin-Tindall, Jake ^{[3
]}

Karolyi-Oezguer, Jale ^{[1
]}

Khan, Shakil ^{[2
,3
]}

Klawatsch, Theresa ^{[1
]}

Koegl, Manfred ^{[1
]}

Kousek, Roland ^{[1
]}

Kratochvil, Barbara ^{[1
]}

Kropatsch, Katrin ^{[1
]}

Lauber, Arnel A. ^{[1
]}

Mclennan, Ross ^{[2
,3
]}

Olt, Sabine ^{[1
]}

Peter, Daniel ^{[1
]}

Petermann, Oliver ^{[1
]}

Roessler, Vanessa ^{[1
]}

Stolt-Bergner, Peggy ^{[1
]}

Strack, Patrick ^{[1
]}

Strauss, Eva ^{[1
]}

Trainor, Nicole ^{[3
]}

Vetma, Vesna ^{[2
,3
]}

Whitworth, Claire ^{[3
]}

Zhong, Siying ^{[3
]}

Quant, Jens ^{[1
]}

Weinstabl, Harald ^{[1
]}

Kuster, Bernhard ^{[4
]}

Ettmayer, Peter ^{[1
]}

Ciulli, Alessio ^{[2
,3
]}

机构：

[1] Boehringer Ingelheim RCV GmbH & Co KG, A-1221 Vienna, Austria

[2] Univ Dundee, Ctr Targeted Prot Degradat, Sch Life Sci, Dundee DD1 5JJ, Scotland

[3] Univ Dundee, Div Biol Chem & Drug Discovery, Sch Life Sci, James Black Ctr, Dundee DD1 5EH, Scotland

[4] Tech Univ Munich, Sch Life Sci, Prote & Bioanalyt, D-85354 Freising Weihenstephan, Germany

[5] Boehringer Ingelheim Pharmaceut, Ridgefield, CT 06877 USA

来源：

SCIENCE | 2024年 / 385卷 / 6715期

基金：

英国惠康基金;

关键词：

E3 UBIQUITIN LIGASE; POTENT; OPTIMIZATION; INHIBITOR;

D O I：

10.1126/science.adm8684

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein are highly prevalent in cancer. However, small-molecule concepts that address oncogenic KRAS alleles remain elusive beyond replacing glycine at position 12 with cysteine (G12C), which is clinically drugged through covalent inhibitors. Guided by biophysical and structural studies of ternary complexes, we designed a heterobifunctional small molecule that potently degrades 13 out of 17 of the most prevalent oncogenic KRAS alleles. Compared with inhibition, KRAS degradation results in more profound and sustained pathway modulation across a broad range of KRAS mutant cell lines, killing cancer cells while sparing models without genetic KRAS aberrations. Pharmacological degradation of oncogenic KRAS was tolerated and led to tumor regression in vivo. Together, these findings unveil a new path toward addressing KRAS-driven cancers with small-molecule degraders.

引用

页码：1338 / 1347

页数：10

共 50 条

[21] Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities
Kastl, Johanna M.
Davies, Gareth
Godsman, Eleanor
Holdgate, Geoffrey A.
SLAS DISCOVERY, 2021, 26 (04) : 524 - 533
[22] A non-covalent inhibitor with pan-KRAS potential
Katie Kingwell
Nature Reviews Drug Discovery, 2023, 22 : 622 - 622
[23] Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
Kim, Dongsung
Herdeis, Lorenz
Rudolph, Dorothea
Zhao, Yulei
Boettcher, Jark
Vides, Alberto
Ayala-Santos, Carlos I. I.
Pourfarjam, Yasin
Cuevas-Navarro, Antonio
Xue, Jenny Y.
Mantoulidis, Andreas
Broeker, Joachim
Wunberg, Tobias
Schaaf, Otmar
Popow, Johannes
Wolkerstorfer, Bernhard
Kropatsch, Katrin Gabriele
Qu, Rui
de Stanchina, Elisa
Sang, Ben
Li, Chuanchuan
McConnell, Darryl B. B.
Kraut, Norbert
Lito, Piro
NATURE, 2023, 619 (7968) : 160 - +
[24] Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer
Li, Jiacheng
Liu, Ting
Song, Yuanli
Wang, Mingyu
Liu, Liping
Zhu, Hongwen
Li, Qi
Lin, Jin
Jiang, Hualiang
Chen, Kaixian
Zhao, Kehao
Wang, Mingliang
Zhou, Hu
Lin, Hua
Luo, Cheng
JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (16) : 11034 - 11057
[25] Small-Molecule Inhibition of KRAS through Conformational Selection
Pagba, Cynthia V.
Gupta, Amit K.
Gorfe, Alemayehu A.
ACS OMEGA, 2023, : 31419 - 31426
[26] Small-molecule degraders of cyclin-dependent kinase protein: a review
Yu, Bin
Du, Zekun
Zhang, Yuming
Li, Zhiyu
Bian, Jinlei
FUTURE MEDICINAL CHEMISTRY, 2022, 14 (03) : 167 - 185
[27] Accelerating the Discovery of Next-Generation Small-Molecule Protein Degraders
Schlesiger, Sarah
Toure, Momar
Wilke, Kaelyn E.
Huck, Bayard R.
ALDRICHIMICA ACTA, 2019, 52 (02) : 35 - 49
[28] Degradome analysis to identify direct protein substrates of small-molecule degraders
Jochem, Marco
Schrempf, Anna
Wagner, Lina-Marie
Segal, Dmitri
Cisneros, Jose
Ng, Amanda
Winter, Georg E.
Krijgsveld, Jeroen
CELL CHEMICAL BIOLOGY, 2025, 32 (01)
[29] Small-molecule Modulators Targeting SHP2 for Cancer Therapy
Mi, Dazhao
Li, Yuzhan
Chen, Yihua
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (05) : 498 - 504
[30] Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells
Plangger, Adelina
Rath, Barbara
Hochmair, Maximilian
Funovics, Martin
Hamilton, Gerhard
TRANSLATIONAL ONCOLOGY, 2021, 14 (12):

← 1 2 3 4 5 →